Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 71

Results For "MIT"

5087 News Found

Duke Street Bio receives FDA fast track designation for PARP1-selective inhibitor with CNS activity
Biotech | July 08, 2025

Duke Street Bio receives FDA fast track designation for PARP1-selective inhibitor with CNS activity

Addresses brain metastases harboring BRCA1/2 and/or HRR alterations—an area of high unmet need


EMA and HMA to strengthen Anti-D Immunoglobulin supply chain
News | July 08, 2025

EMA and HMA to strengthen Anti-D Immunoglobulin supply chain

These medicines are essential in preventing RhD immunisation during pregnancy


Veerhealth Care enters into contract manufacturing agreement
News | July 08, 2025

Veerhealth Care enters into contract manufacturing agreement

Commercial production is expected to begin soon


Godavari Biorefineries' anti-cancer patent now validated in Spain and UK
Biotech | July 07, 2025

Godavari Biorefineries' anti-cancer patent now validated in Spain and UK

Anti-cancer patent now validated in Spain, the UK, and as a Unitary Patent covering multiple EU member states


Sigachi Industries appoints Lijo Stephen Chacko as Deputy Group CEO
People | July 07, 2025

Sigachi Industries appoints Lijo Stephen Chacko as Deputy Group CEO

Lijo Chacko is the Chief Executive Officer – Middle East & Africa at Sigachi Industries


SPARC incorporates subsidiary ‘Genokine Biotech’
News | July 07, 2025

SPARC incorporates subsidiary ‘Genokine Biotech’

The wholly owned subsidiary will carry on the business of all types of research and development and other related services


GACL flags of first dispatch of Benzyl Alcohol and Benzaldehyde
News | July 06, 2025

GACL flags of first dispatch of Benzyl Alcohol and Benzaldehyde

The facility will manufacture 13,200 MTPA Benzyl Chloride, 9,600 MTPA Benzyl Alcohol, and 7,200 MTPA Benzaldehyde


Shilpa Pharma Lifesciences Unit-1 inspected by ANVISA
Drug Approval | July 06, 2025

Shilpa Pharma Lifesciences Unit-1 inspected by ANVISA

The audit has been concluded with no major observations